A multi-center, randomized, open-label study of the safety and efficacy of interferon (IFN) α-2b plus ribavirin (RBV) for the treatment of HCV infection in HIV-infected persons : Mark Sulkowski, Johns Hopkins Medical Institutions, Baltimore, MD; Franco Felizarta, Bakersfield, CA, Bakersfield, CA; Cheryl Smith, North General Hospital, New York, NY; Ruth Berggren, University of Texas Southwestern Medical Center, Dallas, TX; Jihad Slim, Saint Michael's Medical Center, Newark, NJ; David Shoultz, PPD Development and University of Washington, Seattle, WA; Lisa Ball, Russ Hudnall, Hepatitis Resource Network, Tacoma, WA; Douglas Dieterich, New York University School of Medicine, New York, NY

Zdroj: In Hepatology 2001 34(4) Part 2:A594-A594
Databáze: ScienceDirect
Externí odkaz: